AUS
NZ
UK
CA
USA
IND
While several ASX healthcare stocks have experienced fluctuations in their share prices, ResMed Inc. (ASX:RMD) recently faced a 2% dip, trading at $22.90 during Tuesday's afternoon session. This decline might represent a compelling buying opportunity, particularly as analysts from Citi remain optimistic about the stock's potential for substantial gains.
Citi's Positive Assessment:
Citi analysts have once again expressed their bullish outlook on A, predicated on the positive insights gleaned from Philips, a significant competitor in the healthcare industry.
Citi's Bullish View:
Citi's assessment of Philips' recent quarterly update has prompted a reaffirmation of its "buy" rating on ResMed shares, accompanied by a price target of $39.00. Such a price target suggests a significant potential upside of around 70% for investors over the next year.
Positive Implications from Philips:
The foundation of Citi's optimistic stance on ResMed hinges on its interpretation of comments made by Philips in their quarterly update. Philips has been grappling with a significant product recall but appears reluctant to re-enter the market with significant discounts. Citi interprets this decision as a favorable indication for ResMed.
GLP-1s and an Undiagnosed Patient Segment:
Furthermore, Citi notes that Philips does not foresee a substantial impact from GLP-1s, such as Ozempic, which are often regarded as effective weight loss medications. Since a considerable portion of individuals suffering from sleep apnea fall into the overweight category, Citi believes there is a substantial pool of undiagnosed patients.
Growth Prospects and Attractive Valuations:
In sum, Citi is confident in ResMed's potential for short-term growth, particularly due to its shares trading at attractive valuations. The broker emphasizes that ResMed's consensus estimates indicate a modest 6% compound annual growth rate for Devices sales from FY23 to FY26, which is in line with historical market growth. This projection implies that ResMed may be relatively immune to the competitive pressure from entities like Philips or the emergence of GLP-1 medications.
In Closing:
Citi's upbeat assessment and its reaffirmed "buy" rating on ResMed shares, along with the $39.00 price target, indicate the prospect of substantial gains. Despite the recent dip in share prices, the positive implications from Philips and the perceived growth opportunities make ResMed an enticing prospect for investors seeking long-term value in the healthcare sector
